Altea Therapeutics’ Transdermal Delivery Technology to Be Tested with KAI Pharmaceuticals’ Peptides
Companies ally on preclinical and clinical development.!--h2>
Altea Therapeutics entered into a partnership with KAI Pharmaceuticals for the preclinical and clinical development of certain KAI peptides utilizing Altea’s PassPort® Transdermal Delivery System.
Altea also granted KAI an option to receive a worldwide technology license for the further development and commercialization of these novel transdermal products. Should KAI exercise the option, KAI will fund all product development, manufacturing, and commercialization activities. As a result, Altea would receive license payments, development and commercialization milestones, and royalties on product sales from KAI.
“While we continue to apply our transdermal technology to currently approved drugs that previously were administered by needle injection or infusion, including water-soluble proteins, carbohydrates, and small molecules, this new partnership allows us to apply our technology to the new peptide drugs being developed by KAI Pharmaceuticals,” points out Eric Tomlinson, Ph.D., president and CEO of Altea Therapeutics.
Altea Therapeutics has partnered with Amylin Pharmaceuticals and Eli Lilly to develop and commercialize a daily transdermal patch to deliver sustained levels of type 2 diabetes drug exenatide (currently marketed as Byetta®). The company is also working with Hospira to develop and commercialize a transdermal patch for delivering enoxaparin sodium (currently marketed as Lovenox®), a treatment for deep vein thrombosis.
Altea Therapeutics also has a transdermal basal insulin patch for diabetes and a transdermal fentanyl citrate patch for pain in clinical development.